Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Endocannabinoid system in psychotic and mood disorders, a review of human studies
Ranjini Garani Ramesh, Jeremy J. Watts, Romina Mizrahi
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 106, pp. 110096-110096
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Parkinson disease psychosis: from phenomenology to neurobiological mechanisms
Javier Pagonabarraga, Helena Bejr‐Kasem, Saül Martínez‐Horta, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 3, pp. 135-150
Closed Access | Times Cited: 16
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Zdeněk Fišar
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2022) Vol. 120, pp. 110626-110626
Closed Access | Times Cited: 59
A review of the effects of different types of social behaviors on the recruitment of neuropeptides and neurotransmitters in the nucleus accumbens
Johnathan M. Borland
Frontiers in Neuroendocrinology (2025), pp. 101175-101175
Closed Access | Times Cited: 1
Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia
Gerwyn Morris, Luba Sominsky, Kenneth R. Walder, et al.
Molecular Neurobiology (2022) Vol. 59, Iss. 6, pp. 3485-3503
Closed Access | Times Cited: 30
The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Gerwyn Morris, Ken Walder, Stefan Kloiber, et al.
Pharmacological Research (2021) Vol. 170, pp. 105729-105729
Closed Access | Times Cited: 33
Dysfunction in endocannabinoids, palmitoylethanolamide, and degradation of tryptophan into kynurenine in individuals with depressive symptoms
Stefano Comai, Nicolás A. Núñez, Tobias Atkin, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
The marijuana-schizophrenia multifaceted nexus: Connections and conundrums towards neurophysiology
Pukar Khanal, Vishal S. Patil, B. M. Patil, et al.
Computational Biology and Chemistry (2023) Vol. 107, pp. 107957-107957
Closed Access | Times Cited: 11
Chemistry and pharmacological aspects of furanoid cannabinoids and related compounds: Is furanoid cannabinoids open a new dimension towards the non-psychoactive cannabinoids?
Radhika Anand, Ritu Painuli, Vijay Kumar, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116164-116164
Closed Access | Times Cited: 4
Cannabis-induced psychotic disorder with onset during withdrawal: a brief report of emerging evidence
J. Pinto Cohen, Hugues Petitjean, M. Belen Blasco, et al.
Acta Neuropsychiatrica (2024) Vol. 36, Iss. 5, pp. 325-329
Open Access | Times Cited: 3
Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study
Michael Specka, Udo Bonnet, Lisa Marie Schmidberg, et al.
Pharmacopsychiatry (2024) Vol. 57, Iss. 02, pp. 61-68
Closed Access | Times Cited: 3
The Interplay between 2-Arachidonoylglycerol and Anandamide Amidohydrolase in Neuropathy
Iddrisu Ibrahim, Joseph Ayariga, Junhuan Xu, et al.
(2024)
Open Access | Times Cited: 3
Involvement of the TRPV1 receptor and the endocannabinoid system in schizophrenia
Junjie Huang, Huan Huang, Moyin Liu, et al.
Brain Research Bulletin (2024) Vol. 215, pp. 111007-111007
Open Access | Times Cited: 3
Microglial morphological/inflammatory phenotypes and endocannabinoid signaling in a preclinical model of periodontitis and depression
Javier Robledo‐Montaña, César Díaz-García, María Martínez, et al.
Journal of Neuroinflammation (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 3
Targeting the endocannabinoid system: Structural determinants and molecular mechanism of allosteric modulation
Jiayi Yuan, Bo Ram Yang, Guanyu Hou, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103615-103615
Open Access | Times Cited: 8
Fatty Acid-Binding Protein 5 Gene Deletion Enhances Nicotine-Conditioned Place Preference: Illuminating the Putative Gateway Mechanisms
Nicole Roeder, Brittany Richardson, Abrianna Mihalkovic, et al.
Future Pharmacology (2023) Vol. 3, Iss. 1, pp. 108-116
Open Access | Times Cited: 7
Inhibition of fatty acid amide hydrolase reverses aberrant prefrontal gamma oscillations in the sub-chronic PCP model for schizophrenia
Alexandre Seillier
Experimental Brain Research (2024) Vol. 242, Iss. 5, pp. 1149-1160
Closed Access | Times Cited: 2
The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study
Madis Parksepp, Liina Haring, Kalle Kilk, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 243-243
Open Access | Times Cited: 12
In silico analyses of the involvement of GPR55, CB1R and TRPV1: response to THC, contribution to temporal lobe epilepsy, structural modeling and updated evolution
Amy L. Cherry, Michael Wheeler, Karolina Mathisova, et al.
Frontiers in Neuroinformatics (2024) Vol. 18
Open Access | Times Cited: 2
Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats
Francesca Frescura, Tibor Štark, Edoardo Tiziani, et al.
Pharmacological Reports (2024) Vol. 76, Iss. 4, pp. 887-894
Closed Access | Times Cited: 2
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
Rafael Vitor Lima da Cruz, Richardson N. Leão, Thiago C. Moulin
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 2
Genetic variation of the 5‐HT1A rs6295, 5‐HT2A rs6311, and CNR1 rs1049353 and an altered endocannabinoid system in depressed patients
Jasmin Obermanns, H. Meiser, S.M. Hoberg, et al.
Brain and Behavior (2023) Vol. 13, Iss. 12
Open Access | Times Cited: 6
Metabolomics, Lipidomics, and Antipsychotics: A Systematic Review
Kyle J. Burghardt, Megan Kajy, Kristen M. Ward, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3295-3295
Open Access | Times Cited: 5
A honokiol-enriched Magnolia officinalis Rehder & E.H. Wilson. bark extract possesses anxiolytic-like activity with neuroprotective effect through the modulation of CB1 receptor
Vittoria Borgonetti, Paolo Governa, Fabrizio Manetti, et al.
Journal of Pharmacy and Pharmacology (2021) Vol. 73, Iss. 9, pp. 1161-1168
Closed Access | Times Cited: 12
Identification of a novel fatty acid binding protein-5-CB2 receptor-dependent mechanism regulating anxiety behaviors in the prefrontal cortex
Taygun C. Uzuneser, Hanna J. Szkudlarek, Matthew Jones, et al.
Cerebral Cortex (2022) Vol. 33, Iss. 6, pp. 2470-2484
Open Access | Times Cited: 8
Alterations in plasma endocannabinoid concentrations among individuals with major depression treated with electroconvulsive therapy
Esther Bloemhof‐Bris, David Meiri, Liron Sulimani, et al.
Psychiatry Research (2024) Vol. 337, pp. 115967-115967
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top